Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix in talks to buy US rival Cellright

There was no certainty yet that the acquisition will go ahead
picture of surgical operation
Tissue engineering is a rapidly growing business

Regenerative medicine specialist Tissue Regenix PLC (LON:TRX) has confirmed talks to buy US rival Cellright.

In a brief statement, the Leeds-based group said a temporary restraining order had been applied for by one of Cellright Technologies LLC’s members against the sale to Tissue.

Following the application Tissue Regenix confirmed discussions were underwa though it said there was no certainty yet that the acquisition will go ahead.

No other details were released.

Texas-based Cellright make a range of regenerative and graft products, notably Matrix 01 a human bone cell scaffold that is processed using the US company’s BioRinse technology. 

Tissue Regenix supplies skin, cartilages, ligaments and valves for grafts from both animals and human tissue banks that have been washed and the acellular scaffold kept intact.

PhilW.jpg
Why Invest In Tissue Regenix Group PLC? Read More Here

Register here to be notified of future TRX Company articles
View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use